A Major Pivot for Global Bio-Manufacturing
In a significant move for the biotech industry, Novonesis—the global leader in biosolutions—has announced a €600 million (approximately ₹6,660 crore) investment to expand its manufacturing footprint in India. The project centers on the Patalganga facility, which is slated to become one of the most technologically advanced enzyme production sites in the world.
The expansion comes as the demand for biological solutions grows rapidly across global sectors. By building this next-generation facility, Novonesis aims to strengthen its supply chain resilience while positioning itself closer to key growth markets in the Middle East, India, and Africa.
Driving Sustainable Growth by 2030
The Patalganga site is expected to reach full operational capacity by 2030. The facility will be dedicated to producing enzymes for critical industries, including:
- Biofuels production
- Household cleaning and laundry detergents
- Food and beverage manufacturing
Beyond mere capacity expansion, the facility is designed to meet strict sustainability standards. Novonesis has confirmed the inclusion of advanced water recycling systems and integrated heat pumps to minimize energy consumption. This initiative aligns with the company's long-term goal of achieving lower Scope 1 and 2 greenhouse gas emissions.
Every facility we build should produce more with less. Patalganga brings together what we have learned across our production footprint and takes us another step toward zero-emission production.
— Anders Lund, Chief Operating Officer, Novonesis
Why This Matters for the Biotech Market
Novonesis was formed in 2024 through the merger of Novozymes and Chr. Hansen. This latest investment is part of a broader, aggressive strategy to scale global production following that historic union. With existing expansions already completed or underway in Thailand, the United States, China, and Brazil, the company is signaling that the era of biosolutions is a key driver for future economic and environmental change.
By bringing production closer to high-growth markets, Novonesis is addressing the fragility of global supply chains. As CEO Ester Baiget noted, this investment reflects a commitment to supporting global customers while generating long-term shareholder value through innovation.